

1 **Rapid response flow cytometric assay for the detection of antibody**  
2 **responses to SARS-CoV-2**

3 **Dennis Lapuente<sup>1</sup>, Clara Maier<sup>1</sup>, Pascal Irrgang<sup>1</sup>, Julian Hübner<sup>1</sup>, Sophia Peter<sup>1</sup>,**  
4 **Markus Hoffmann<sup>2</sup>, Armin Ensser<sup>1</sup>, Katharina Ziegler<sup>3</sup>, Thomas H. Winkler<sup>4</sup>, Torsten**  
5 **Birkholz<sup>5</sup>, Andreas E. Kremer<sup>6</sup>, Philipp Steininger<sup>1</sup>, Klaus Korn<sup>1</sup>, Frank Neipel<sup>1</sup>, Klaus**  
6 **Überla<sup>1</sup>, Matthias Tenbusch<sup>1</sup>**

7 <sup>1</sup> Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-  
8 Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; <sup>2</sup> Infection Biology  
9 Unit, German Primate Center - Leibniz Institute for Primate Research, 37077 Göttingen,  
10 Germany; <sup>3</sup> Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus  
11 Medical University, Nürnberg, Germany; <sup>4</sup> Department of Biology, Division of Genetics,  
12 Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander University Erlangen-  
13 Nürnberg, Erlangen, Germany; <sup>5</sup> Department of Anaesthesiology, University Hospital  
14 Erlangen, Erlangen, Germany; <sup>6</sup> Department of Medicine 1, Gastroenterology, Pneumology  
15 and Endocrinology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-  
16 Nürnberg, 91054 Erlangen, Germany; Address for correspondence: Dennis Lapuente, Institute  
17 of Clinical and Molecular Virology, University Hospital Erlangen, Schlossgarten 4, 91054  
18 Erlangen, Germany; E-mail: [Dennis.Lapuente@uk-erlangen.de](mailto:Dennis.Lapuente@uk-erlangen.de)

19

20 **Abstract**

21 SARS-CoV-2 has emerged as a previously unknown zoonotic coronavirus that spread  
22 worldwide causing a serious pandemic. While reliable nucleic acid-based diagnostic assays  
23 were rapidly available, there exists only a limited number of validated serological assays.  
24 Here, we evaluated a novel flow cytometric approach based on antigen-expressing HEK 293T  
25 cells to assess spike-specific IgG and IgM antibody responses. Analyses of 201 pre-COVID-  
26 19 sera proved a high assay specificity in comparison to commercially available CLIA and  
27 ELISA systems, while also revealing the highest sensitivity in specimens from PCR-  
28 confirmed SARS-CoV-2 infected patients. Additionally, a soluble Angiotensin-Converting-  
29 Enzyme 2 (ACE-2) variant was established as external standard to quantify spike-specific  
30 antibody responses on different assay platforms. In conclusion, our newly established flow  
31 cytometric assay allows sensitive and quantitative detection of SARS-CoV-2-specific

32 antibodies, which can be easily adopted in different laboratories and does not rely on external  
33 supply of assay kits.

## 34 **Introduction**

35 In early December 2019, a novel zoonotic coronavirus (CoV) caused a cluster of pneumonia  
36 cases in Wuhan, China (1). Since then, the virus has spread globally and caused a pandemic  
37 with over 3,435,000 confirmed infections and about 240,000 fatalities (as of May 4<sup>th</sup> 2020)  
38 (2). Due to its phylogenetic similarity to the Severe Acute Respiratory Syndrome Related  
39 Coronavirus (SARS-CoV-1), the novel CoV was named SARS-CoV-2 (3). The acute  
40 respiratory disease induced by SARS-CoV-2 is called coronavirus disease 19 (COVID-19).

41 The identification of acutely infected individuals by the detection of viral RNA by real-time  
42 PCR (4) was implemented rapidly in the health care of most countries. While this method is  
43 highly valuable for the diagnosis of acute COVID-19 cases, specific serological methods are  
44 urgently needed to determine seroconversion in general and more specifically to characterize  
45 the humoral response against SARS-CoV-2. Robust, validated serological approaches are  
46 essential to track transmission events in individuals that have already cleared the infection  
47 especially after mild or symptom-free disease. With increasing numbers of immune  
48 individuals, serological tests will also help to understand epidemiological aspects of the  
49 pandemic and to employ SARS-CoV-2 immune staff in critical frontline positions at hospitals  
50 or nursing homes. In addition, validated serological methods are essential to evaluate novel  
51 vaccine candidates in clinical studies.

52 Together with the 2003 SARS-CoV-1 and the 2012 Middle East Respiratory Syndrome  
53 Coronavirus (MERS-CoV) epidemic, the SARS-CoV-2 pandemic represents the third  
54 betacoronavirus in twenty years that crossed the species barrier and resulted in a significant  
55 number of human infections. At the same time, four other CoVs are endemic in the human  
56 population (two alphacoronaviruses: CoV-NL63 and -229E, two betacoronaviruses: CoV-

57 OC43 and -HKU1) that cause episodes of common cold in humans in all parts of the world  
58 (5). CoVs are enveloped single-stranded RNA viruses that contain four structural proteins:  
59 membrane (M), envelope (E), spike (S), and nucleocapsid (N). From SARS-CoV-1 it is  
60 known that N and S proteins are the most immunogenic viral antigens, while only S-specific  
61 antibodies can mediate virus neutralization (6,7). Therefore, N- and S-specific antibody  
62 responses should be first choice parameters for a sensitive serology (8). However, depending  
63 on the study cohort, up to 90% of the population is seropositive for common cold CoVs (9–  
64 11). Thus, a careful validation of the assay specificity is required in CoV serology.

65 Here, we describe a novel flow cytometric assay to determine SARS-CoV-2 spike protein-  
66 specific antibodies in serum samples. The virus-free assay relies on reagents and devices that  
67 are available in many medical and biological research labs and therefore can be easily adopted  
68 in a decentral manner without the need for commercial kits or products that are prone to  
69 shortage.

## 70 **Materials and methods**

### 71 **Serum samples**

72 Anonymized, random sera (n=180) were selected from the sample repository of the  
73 diagnostics department of the Institute for Clinical and Molecular Virology at the University  
74 Hospital Erlangen to evaluate the specificity of the novel diagnostic test. Samples were  
75 collected until August 2019 (further denominated as pre-COVID-19 era) and no longer  
76 needed for diagnostic purposes and assigned for disposal. Those specimens were not  
77 characterized in regard to anti-HCoV antibody status. 21 sera from eight patients with PCR-  
78 confirmed endemic HCoV infections were additionally included. These samples were  
79 collected at least one week before and two to four weeks after HCoV infection. These include  
80 4x HKU-1, 2x 229E, 1x NL63, 1x OC43 infections. Post-infection sera were sampled twice  
81 from some patients (Table 1). Additionally, 60 specimens from 34 individuals with a PCR-

82 confirmed SARS-CoV-2 infection (some sampled longitudinally) were obtained. The majority  
83 is derived from a newly established biobank for COVID-19 patients at the University Hospital  
84 Erlangen. The data are collected in accordance with ethical requirements. The  
85 implementation of the biobank has been approved by the local ethics committee of the UK  
86 Erlangen under the licence number AZ. 174\_20 B. Five out of 60 were derived from plasma  
87 donors after (patients' informed consents; approved by local ethics committee of the FAU;  
88 AZ. 2020, 49\_20B). Another set of sera was collected from thirteen COVID-19 patients at the  
89 Hospital Nürnberg Nord at different time points after the PCR-confirmation (Table 2). All  
90 sera were sampled for recent diagnostic purpose and have been tested for seroconversion in  
91 the EuroImmun ELISA at the Institute of Clinical Hygiene, Medical Microbiology and  
92 Infectiology, Paracelsus Medical University, Hospital Nürnberg, Germany. All clinical  
93 specimen were used in anonymous form for retrospective analyses.

#### 94 **DNA plasmids**

95 The pCG1\_CoV\_2019-S plasmid encoding the codon-optimized sequence of the SARS-CoV-  
96 2 S protein was generated as described elsewhere (12). The plasmid pcDNA3.1 (Invitrogen)  
97 was used in the mock transfection control. Blue fluorescent protein (BFP) and red fluorescent  
98 protein-encoding (dsRed; from *Discosoma sp.*) plasmids were used as marker proteins for  
99 transfected 293T cells.

#### 100 **Flow cytometric antibody assay**

101 Human embryonic kidney cells (HEK 293T cells; ECACC 12022001) were maintained in  
102 Dulbecco's modified Eagle's medium (DMEM; Gibco, Cat #11960-044) containing 10% fetal  
103 calf serum (Capricorn Scientific, Cat #FBS-12A), 1% GlutaMAX (Gibco, Cat #35050-038),  
104 and 1% Penicillin/Streptomycin (Gibco, Cat #15140-122) at 37°C and 5% CO<sub>2</sub>. For the assay,  
105  $1.12 \times 10^7$  cells were plated out (25 ml medium; 175 cm<sup>2</sup> cell culture flask) and, 12-24 hours  
106 later, were transfected with 30 µg pCG1\_CoV\_2019-S plus 15 µg fluorescent protein (BFP)

107 by standard polyethylenimine transfection (3.5 ml DMEM, 67.5 µg polyethylenimine). As an  
108 internal control, a mock transfection was used with 30µg pcDNA3.1 and 15µg fluorescent  
109 protein (dsRed). 48 hours after the transfection, cells were harvested, resuspended in freeze  
110 medium (75% FCS, 10% DMSO, 3% Glucose in DMEM), and stored in 1 ml aliquots of  
111  $1 \times 10^7$  cells at  $-80^{\circ}\text{C}$ .

112 For the assay, aliquots of cells were thawed, washed once with PBS, and then resuspended in  
113 FACS buffer (PBS with 0.5% bovine serum albumin and 1 nmol sodium azide).  $0.5 \times 10^5$  cells  
114 of each of the two cell preparations (S- and mock-transfected) were seeded out per sample in  
115 a 96-well U-bottom plate. Serial dilutions of the standards or serum samples (1:100) were  
116 diluted in 100 µl FACS buffer and given on the cells (30 min,  $4^{\circ}\text{C}$ ). 100 µl FACS buffer was  
117 added, cells were centrifuged (500 xg,  $4^{\circ}\text{C}$ , 3min; used for all following centrifugation steps),  
118 washed two times with 180 µl FACS buffer, and bound antibodies were stained with  
119 secondary detection antibodies diluted 1:300 in 100 µl FACS buffer (30 min,  $4^{\circ}\text{C}$ , anti-IgG-  
120 AF647, clone HP6017, Biolegend, Cat #409320; anti-IgM-BV711, clone MHM-88,  
121 Biolegend, Cat #314540). 100 µl PBS was added, cells were centrifuged, washed two times  
122 with 180 µl PBS, and fixed in 200 µl 2% paraformaldehyde in PBS (15 min,  $4^{\circ}\text{C}$ ). Cells were  
123 centrifuged and washed once in 180 µl FACS buffer, before resuspended in 200 µl FACS  
124 buffer for flow cytometric analysis. Data were acquired on a BD LSR II or Thermo Fisher  
125 Attune Nxt cytometer and analysis was performed with FlowJo (Tree Star Inc.) or Flowlogic  
126 (Inivai Technologies).

### 127 **ACE-2-Fc standard**

128 A PCR fragment containing the sequence coding for the extracellular domain of human ACE-  
129 2 lacking the secretory signal peptide (NM\_021804.3, nucleotides 358 – 2520) fused at the 3'  
130 end with a PCR fragment coding for the Fc-part of human IgG1 and a C-terminal myc/his tag  
131 was cloned into the expression vector pCEP4 (Thermo Fisher Scientific). The signal peptide

132 of the murine IgG kappa-chain V-J2 was used instead of the ACE-2 signal peptide. The  
133 synthetic intron from pIRES (IVS, Takara Bio) was cloned via NheI restriction sites between  
134 the transcription start and the translation start site. Expression and purification of the Fc-  
135 fusion protein was done as described before (13). Briefly, HEK 293T cells were transfected  
136 by calcium phosphate method and kept in culture for six days. Cell culture supernatant was  
137 then harvested and cell debris removed by centrifugation. The pH of the supernatant was  
138 adjusted to 8.0 with NaOH and sterile filtered. The supernatant was then applied to a HiTrap  
139 Protein A HP column (GE Healthcare Life Sciences). ACE-2-Fc fusion protein was eluted by  
140 a pH step gradient using 0.1 M citrate buffer. ACE-2 Fc fusion protein eluted at pH 4.0 and  
141 the pH was immediately neutralized by the addition of 1M Tris buffer (pH 9).

142 As an external standard for IgG quantitation, a two-fold dilution series starting with 10 µg/ml  
143 of ACE-2-Fc was measured in the flow cytometric assay as described above. With this  
144 standard, we quantified the amount of ACE-2-binding equivalents in a plasma sample  
145 available in larger volume. Adjusting for molecular weight differences between ACE2-Fc and  
146 IgG, the anti-SARS-CoV-2 S IgG concentration in this plasma sample was determined.

#### 147 **Enzyme-linked Immunosorbent Assay (ELISA)**

148 Commercially available ELISA for the detection of anti-SARS-CoV-2 IgG (anti-S1-specific,  
149 EuroImmun, Cat #EI 2606-9601 G) and IgA (EuroImmun, Cat #EI 2606-9601 A) were  
150 performed according to the manufacturer's protocols. Sera were diluted 1:101 (10µl sample +  
151 1000µl sample buffer) and the optical density was detected at 450 nm at a multilabel plate  
152 reader (Victor X5, Perkin Elmer). A cut-off for a positive result was according to the  
153 manufacturer defined as a ratio of >1.1 between the specific specimen and the calibrator.  
154 Values between 0.8 and 1.1 were defined as "borderline".

#### 155 **Chemiluminescent Immunoassay (CLIA)**

156 Commercially available magnetic bead-based CLIA for the detection of IgG (N- and S-  
157 specific, Shenzhen Yhlo Biotech, iFlash-SARS-CoV-2, Cat #C86095G) and IgM (Shenzhen  
158 Yhlo Biotech, iFlash-SARS-CoV-2, Cat #C86095M) were performed on a fully automated  
159 iFlash Immunoassay Analyzer (Shenzhen Yhlo Biotech). The assays were performed  
160 according to the manufacturer's protocols. The IgG and IgM titer were automatically  
161 calculated as arbitrary units (AU/ml) and the cut-off value for a positive test was 10 AU/ml.

## 162 **Results**

### 163 **Assay specificity for SARS-CoV-2 immune sera**

164 The novel serological assay we evaluate here exploits 293T cells that express full-length  
165 SARS-CoV-2 spike protein in its natural conformation to bind antigen-specific IgM and IgG  
166 from patient sera with a subsequent quantification by secondary detection antibodies. In a  
167 multiplex approach with two populations each co-expressing a specific fluorescent protein  
168 (dsRed or BFP), non-antigen-expressing cells provide an internal specificity control. By this,  
169 one can control for unspecific binding of antibodies to cellular components leading to  
170 potentially false-positive results for example in patients with autoimmune diseases.

171 Figure 1 illustrates the gating strategy and the respective IgM and IgG mean fluorescence  
172 intensity (MFI) signals for three negative controls and three SARS-CoV-2 convalescent sera.  
173 None of the negative control sera S4-S6 led to a significant MFI increase in the S-expressing  
174 population compared to the mock control cells. In contrast, both for IgM and IgG, the MFI in  
175 the S-expressing cells were clearly increased compared to the mock cells indicating a specific  
176 binding of S-specific antibodies. Subsequently, we defined two cut-off criteria for a positive  
177 serological result: (i) the MFI of the test sample must be at least three-fold higher compared to  
178 the mean of three negative sera tested in parallel and (ii) the ratio of MFI SARS-CoV-2/MFI  
179 mock must be higher than 3.

180 We evaluated the assay specificity and sensitivity with a set of 180 historic diagnostic  
181 samples that had not been analysed for antibody responses to endemic HCoV, with 21 sera  
182 derived from eight patients with confirmed endemic HCoV infections (pre- and post-infection  
183 sera sampled), as well as with 60 sera from SARS-CoV-2 PCR-positive individuals (Table 1).  
184 The results for IgM and IgG (MFI SARS-CoV-2/MFI mock ratios) are shown for a  
185 representative set of specimen in figure 2 and a summary of all sera tested for S-specific  
186 antibody responses is provided in table 1. With the cut-off criteria defined above, 60 out of 60  
187 specimen collected from PCR-confirmed SARS-CoV-2 patients were IgG-positive (100%)  
188 and 48 out of 55 were tested IgM-positive (84.2%; not all samples characterized for IgM). Of  
189 note, the negative testing for IgM occurred in serum samples, which were still IgG positive  
190 and sampled most probably in the later stage of convalescence. Regarding the specificity of  
191 the assay, IgM exceeded the cut-off criteria only in patients with a previously PCR-confirmed  
192 SARS-CoV-2 infection, while none of the sera from uninfected individuals did so (0/105). For  
193 IgG, two out of 180 sera (1.1 %) sampled in the pre-COVID-19 era without any information  
194 about HCoV status surpassed the criteria for seroconversion. Importantly, none of the sera  
195 with a PCR-confirmed endemic HCoV infection (sampled 2-4wks post-infection) showed any  
196 IgG or IgM cross-reactivity, thus, indicating a high degree of assay specificity for SARS-  
197 CoV-2 seroconversion.

198 A longitudinal analysis of a patient starting at the day of PCR-confirmed SARS-CoV-2  
199 infection (3<sup>th</sup> April, day 0) presented specific seroconversion for IgG around day 8 (11<sup>th</sup> April)  
200 and for IgM around day 10 (13<sup>th</sup> April) although showing elevated levels of IgM below the  
201 cut-off already earlier (Fig. 3A). A second patient presented earlier IgM (day 3, 30<sup>th</sup> March)  
202 than IgG seroconversion (day 7; Fig. 3B), but it is important to note that the exact infection  
203 events are unknown in both cases.

204 **Performance compared to commercial kits**

205 We further assessed thirteen serum samples from PCR-confirmed cases of SARS-CoV-2  
206 infections in a comparative analysis with our flow cytometric assay, a commercial ELISA for  
207 IgA/IgG (spike subunit S1-specific; EuroImmun), and a commercial CLIA (N- and S-specific;  
208 Shenzhen Yhlo Biotech). Among those thirteen samples, eight were positive for SARS-CoV-  
209 2-specific antibodies in all assays, while two specimens were uniformly negative (Table 2).  
210 Of note, those two sera were sampled at the day of PCR-confirmation, thus, seroconversion  
211 might not yet have been occurred. Similarly, another specimen (sample 3) was sampled at the  
212 same day as the first positive PCR test and showed IgG/IgM seroconversion in the flow  
213 cytometric assay, but did not show reactivity in the CLIA and only borderline reactivity in the  
214 IgG ELISA (“borderline” as defined by manufacturer). The flow cytometric serological assay  
215 for IgG and IgM as well as the ELISA for IgA showed the highest sensitivity with 11/13  
216 specimens above the cut-off. Two sera were borderline positive in the IgG ELISA, while both  
217 positive in the flow cytometric assay and one positive in the IgG CLIA. Overall, this  
218 demonstrates a high sensitivity of our cytometric antibody detection for seroconversion in a  
219 direct comparison to commercially available detection kits. The lower detection limit was also  
220 confirmed by serial dilutions of selected positive samples. While 1-10,000 dilutions were still  
221 measured as seropositive by our flow cytometric assay, the two other kits revealed a negative  
222 result suggesting a higher analytical sensitivity of the flow cytometric test (data not shown).

### 223 **ACE-2-Fc as external standard for absolute quantification of samples**

224 In order to allow quantitation of antibody responses, we developed an external standard based  
225 on the soluble SARS-CoV-2 entry receptor ACE-2 (12,14) fused to a human IgG fragment  
226 crystallizable region (Fc region). As depicted in figure 4A, the ACE-2-Fc standard binds to  
227 SARS-CoV-2-expressing HEK 293T cells in a concentration-dependent manner with a linear  
228 incline before a saturation phase at higher concentrations. The MFIs of the standard curve  
229 demonstrate a strong reproducibility with low inter-assay variation (Fig. 4A) and allow

230 absolute quantitation of in-house standard sera or plasma. The anti SARS-CoV-2 IgG  
231 concentration in our standard plasma was determined using the linear range of the  
232 recombinant ACE2-Fc protein as standard. After adjustment for molecular weight differences,  
233 the standard plasma had a concentration of 1.01 mg/ml anti-SARS-CoV-2 S IgG. Aliquots of  
234 this plasma sample were used as standards for quantification of seven randomly selected sera  
235 in the flow cytometric assay (Fig. 4B) and the EuroImmun ELISA (Fig. 4C), respectively.  
236 This revealed a good correlation for the two quantification methods (Fig. 4 D). Within PCR-  
237 positive individuals, the flow cytometric assay could monitor serum antibody responses to the  
238 SARS-CoV-2 S protein in the range of 10 µg/ml (mild cases) up to 6 mg/ml in severely sick  
239 patients. Thus, this quantification provides an objective value of SARS-CoV-2 spike-binding  
240 IgG concentrations in a given sample that can be compared among different assays and  
241 laboratories.

## 242 **Discussion**

243 While rigorous measures led to a partial control of the recent SARS-CoV-2 pandemic in some  
244 countries, validated serological assays are urgently needed to consolidate those achievements  
245 and to support the transition to a post-peak phase. This includes for example diagnostic  
246 measures for late/post infection stages, COVID-19 contact tracing, the assessment of  
247 epidemiological aspects, and the evaluation of immunity after infection or in potential vaccine  
248 trials. In the recent study, we validated an in-house flow cytometric assay for the detection of  
249 SARS-CoV-2 S-specific IgM and IgG using sera from PCR-confirmed COVID-19 cases and  
250 a collection of control serum samples. In regard to specificity and sensitivity, our flow  
251 cytometric assay showed a comparable or even better performance compared to commercial  
252 CE-marked serological assays (EuroImmun ELISA and Shenzhen Yhlo CLIA).

253 Detection of viral nucleic acids via real time PCR is the gold standard in the diagnosis of  
254 acute SARS-CoV-2 infections. However, despite its reliability early during infection,

255 confirmation of an infection at later time points becomes less reliable. As early as eight days  
256 post-infection, the diagnostic value of serological assays might therefore outperform nucleic-  
257 acid-based methods (15,16). Indeed, also our study showed seroconversion in a longitudinal  
258 set of sera from one patient eight days after the first positive PCR test, although the exact  
259 infection date is not clearly defined. As reported before (15,17,18), IgM did not generally  
260 possess a higher clinical sensitivity compared to IgG, since most of the seropositive specimen  
261 tested in the present study were positive for both isotypes. Detection of SARS-CoV-2-specific  
262 IgA was previously reported as more sensitive than detection of IgG in the EuroImmun  
263 ELISA kits (19). However, while this held also true in our study, IgG and IgM measured by  
264 the flow cytometric assay were similarly sensitive compared to the IgA ELISA. This higher  
265 sensitivity to detect S-specific IgG might be due to the different viral antigens used in the  
266 assays. Our flow cytometric assay exploits full-length S protein in its natural conformation  
267 and with the respective posttranslational modifications due to the expression in mammalian  
268 cells. This enables detection of the full spectrum of S-specific antibodies directed against  
269 conformational epitopes and glycosylated sites as well, some immunogenic sites possibly  
270 missing in truncated, recombinant S1-only proteins as used in the EuroImmun ELISA.

271 A potential downside of using full-length S for serological testing might be the detection of  
272 cross-reactive antibodies induced by other HCoV. Along this line, some assays detect only  
273 antibodies directed against the S1 subunit (like the EuroImmun ELISA) or the receptor  
274 binding domain in order to increase specificity (19,20). However, in a collection of sera from  
275 individuals that suffered from an infection with an endemic HCoV shortly before blood  
276 collection, none was tested positive for SARS-CoV-2 antibodies. In additional 180 specimens  
277 sampled before the COVID-19 outbreak, two sera were found to be reactive in the flow  
278 cytometric assay. Since endemic HCoV seroprevalence is high in the general population (11)  
279 and those two individuals were non-reactive in the commercial S1-specific ELISA, a plausible  
280 explanation is cross-reaction of antibodies induced by the endemic HCoVs with the S2

281 subunit of SARS-CoV-2. Although the reactivity of the two specimens need to be classified as  
282 false-positive detection of SARS-CoV-2 antibodies, these cross-reactive antibodies might  
283 possess antiviral activity against COVID-19 and the analysis of cross-protection due to these  
284 responses might be an interesting topic for further investigations. Although a clinical  
285 specificity of about 99% seems high, the positive predictive value of commonly used antibody  
286 tests under the currently expected SARS-CoV-2 seroprevalence rates in many countries of 1-  
287 2% is low. While this may be controlled for in seroepidemiological studies, confirmatory tests  
288 are urgently needed if serological assays are to be used for individual diagnosis of past SARS-  
289 CoV-2 infections.

290 Regarding the clinical sensitivity, the flow cytometric serology assay detected 100% of IgM  
291 and IgG positive samples measured by either of the two commercial assays. Only in cases  
292 where blood samples were taken at the same day as PCR sampling, all assays (ELISA, CLIA,  
293 cytometry) were negative, probably reflecting acute infections prior to development of  
294 detectable antibody responses. The lower analytical detection limit of the flow cytometric  
295 assay is consistent with its excellent clinical sensitivity.

296 As the demand for SARS-CoV-2 serology testing kits increases worldwide and only a limited  
297 number of suppliers have developed such kits yet, there is a high need to expand the portfolio  
298 of serology techniques to meet this demand. The flow cytometry-based technique to detect  
299 SARS-CoV-2 seroconversion presented here, fulfils fundamental criteria in regard to  
300 sensitivity, specificity, and robustness. Therefore, we think that this method combines a  
301 moderate workload without the need for critical components and the possibility for high-  
302 throughput testing and, thus, can expand the existing portfolio. The basic requirements needed  
303 like cell culture, plastic ware, and a flow cytometer are available in many standard diagnostic  
304 and biomedical research labs. Thus, this method can increase serology testing capacities  
305 significantly without competing for ELISA/CLIA kits. Given the large number of antibody

306 assays reaching the market without clearly defined analytical sensitivities, using recombinant  
307 ACE-2 Fc protein for standardization is a potential strategy for cross-assay comparisons.  
308 Moreover, the quantification of S-specific antibody responses might help to define protective  
309 antibody levels as correlate of protective immunity.

310 In conclusion, our in-house flow cytometry-based serological assay has good specificity and  
311 sensitivity for the detection of antibodies to SARS-CoV-2. In addition to the nucleotide  
312 sequence of the antigen, only readily available reagents were needed to establish the assay.  
313 Therefore, the flow cytometric assay may also serve as a rapid-response antibody test against  
314 other emerging viral infections.

## 315 **References**

- 316 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
317 infected with 2019 novel coronavirus in Wuhan, China. *Lancet* [Internet]. 2020  
318 Feb;395(10223):497–506. Available from:  
319 <https://linkinghub.elsevier.com/retrieve/pii/S0140673620301835>
- 320 2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -  
321 105 [Internet]. 2020. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)  
322 [source/coronaviruse/situation-reports/20200504-covid-19-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)  
323 [105.pdf?sfvrsn=4cdda8af\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2)
- 324 3. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-  
325 nCoV and naming it SARS-CoV-2. *Nat Microbiol* [Internet]. 2020 Apr 2;5(4):536–44.  
326 Available from: <http://www.nature.com/articles/s41564-020-0695-z>
- 327 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of  
328 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*  
329 [Internet]. 2020 Jan 23;25(3). Available from:  
330 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045>
- 331 5. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human  
332 Coronaviruses. In 2018. p. 163–88. Available from:  
333 <https://linkinghub.elsevier.com/retrieve/pii/S0065352718300010>

- 334 6. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al.  
335 Contributions of the structural proteins of severe acute respiratory syndrome  
336 coronavirus to protective immunity. *Proc Natl Acad Sci* [Internet]. 2004 Jun  
337 29;101(26):9804–9. Available from:  
338 <http://www.pnas.org/cgi/doi/10.1073/pnas.0403492101>
- 339 7. Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R, et al. Antibody responses to individual  
340 proteins of SARS coronavirus and their neutralization activities. *Microbes Infect*  
341 [Internet]. 2005 May;7(5–6):882–9. Available from:  
342 <https://linkinghub.elsevier.com/retrieve/pii/S1286457905000869>
- 343 8. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses:  
344 Challenges and pitfalls. *Virus Res* [Internet]. 2014 Dec;194:175–83. Available from:  
345 <https://linkinghub.elsevier.com/retrieve/pii/S0168170214001257>
- 346 9. Ehrengut W, Sarateanu DE. A two year serological surveillance of coronavirus  
347 infections in Hamburg. *Infection* [Internet]. 1980 Mar;8(2):70–2. Available from:  
348 <http://link.springer.com/10.1007/BF01639150>
- 349 10. Severance EG, Bossis I, Dickerson FB, Stallings CR, Origoni AE, Sullens A, et al.  
350 Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and  
351 Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan Population.  
352 *Clin Vaccine Immunol* [Internet]. 2008 Dec;15(12):1805–10. Available from:  
353 <https://cvi.asm.org/content/15/12/1805>
- 354 11. Gorse GJ, Patel GB, Vitale JN, O’Connor TZ. Prevalence of Antibodies to Four  
355 Human Coronaviruses Is Lower in Nasal Secretions than in Serum. *Clin Vaccine*  
356 *Immunol* [Internet]. 2010 Dec;17(12):1875–80. Available from:  
357 <https://cvi.asm.org/lookup/doi/10.1128/CVI.00278-10>
- 358 12. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.  
359 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a  
360 Clinically Proven Protease Inhibitor. *Cell* [Internet]. 2020 Apr;181(2):271–280.e8.  
361 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294>
- 362 13. Hahn A, Birkmann A, Wies E, Dorer D, Mahr K, Stürzl M, et al. Kaposi’s Sarcoma-  
363 Associated Herpesvirus gH/gL: Glycoprotein Export and Interaction with Cellular  
364 Receptors. *J Virol* [Internet]. 2009 Jan 1;83(1):396–407. Available from:  
365 <https://jvi.asm.org/content/83/1/396>

- 366 14. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of  
367 SARS-CoV-2 by full-length human ACE2. *Science* (80- ) [Internet]. 2020 Mar  
368 27;367(6485):1444–8. Available from:  
369 <https://www.sciencemag.org/lookup/doi/10.1126/science.abb2762>
- 370 15. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-  
371 CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* [Internet]. 2020  
372 Mar 28; Available from: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996)  
373 [article/doi/10.1093/cid/ciaa344/5812996](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996)
- 374 16. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral  
375 Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*  
376 [Internet]. 2020 Mar 21; Available from: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa310/5810754)  
377 [article/doi/10.1093/cid/ciaa310/5810754](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa310/5810754)
- 378 17. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal  
379 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody  
380 responses during infection by SARS-CoV-2: an observational cohort study. *Lancet*  
381 *Infect Dis* [Internet]. 2020 Mar; Available from:  
382 <https://linkinghub.elsevier.com/retrieve/pii/S1473309920301961>
- 383 18. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.  
384 Breadth of concomitant immune responses prior to patient recovery: a case report of  
385 non-severe COVID-19. *Nat Med* [Internet]. 2020 Apr 16;26(4):453–5. Available from:  
386 <http://www.nature.com/articles/s41591-020-0819-2>
- 387 19. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.  
388 Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in  
389 Coronavirus Disease 2019 Patients. *Emerg Infect Dis* [Internet]. 2020 Jul;26(7).  
390 Available from: [http://wwwnc.cdc.gov/eid/article/26/7/20-0841\\_article.htm](http://wwwnc.cdc.gov/eid/article/26/7/20-0841_article.htm)
- 391 20. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al.  
392 Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* [Internet]. 2020  
393 Jan 1;2020.04.09.20056325. Available from:  
394 <http://medrxiv.org/content/early/2020/04/10/2020.04.09.20056325.abstract>
- 395
- 396

397 Table 1. Validation of the flow cytometric assay for SARS-CoV-2-specific IgM and IgG with  
 398 serum samples collected before the COVID-19 outbreak and a set of sera from PCR-  
 399 confirmed SARS-CoV-2 infections

	Samples (# of patients)	IgM+ (%)*	IgM- (%)*	IgG+ (%)	IgG- (%)
Pre-COVID-19 sera	180 (n.d.)	0 (0)	84 (100)	2 (1.1)	178 (98.8)
HCoV+ (endemic, pre)	8 (8)	0 (0)	8 (100)	0 (0)	8 (100)
HCoV+ (endemic, post)	13 (8)	0 (0)	13 (100)	0 (0)	13 (100)
Recent SARS-CoV-2 PCR+	60 (34)	48 (87.3)	7 (12.7)	60 (100)	0 (0)

400 n.d., not determined. \*, IgM testing was not available for initial tests, which explains the  
 401 lower sample number


402

403 Table 2: Analysis of serum samples from COVID-19-infected individuals at various time  
 404 points relative to PCR-confirmation by EuroImmun ELISA, in-house flow cytometric assay,  
 405 and Yhlo CLIA

Sample	Sampling relative to PCR [days]	EuroImmun ELISA				Flow cytometry assay				Yhlo CLIA			
		IgA	IgA Ratio	IgG	IgG Ratio	IgM	IgM Ratio	IgG	IgG Ratio	IgM	AU/ml	IgG	AU/ml
1	0	-	0.4	-	0.2	-	1.9	-	3.1	-	0.54	-	0.52
2	0	-	0.1	-	0.2	-	1.2	-	0.95	-	1.18	-	2.29
3	0	+	1.9	+/-	0.9	+	9	+	24.1	-	5.46	-	1.72
4	0	+	3	+	2.7	+	17	+	90.7	+	362.64	+	30.94
5	+2	+	4.5	+	4.5	+	22.2	+	160	+	104.09	+	49.6
6	+5	+	≥11	+	9.4	+	41	+	112.6	+	254.86	+	61.55
7	+6	+	≥11	+	9.4	+	42.7	+	166.3	+	605.83	+	47.87
8	+7	+	≥11	+	14.5	+	15.4	+	95.9	+	15.47	+	112.52
9	+8	+	≥11	+	12.6	+	56	+	263.3	+	246.58	+	101.62
10	+8	+	4.8	+/-	0.8	+	31	+	103.4	-	6.48	+	16.94
11	+9	+	≥11	+	15.7	+	52	+	321.8	+	106.43	+	161.04
12	+12	+	10.1	+	5.6	+	48.3	+	345.5	+	43.27	+	186.03
13	+14	+	≥11	+	14	+	37.1	+	261.5	-	7.76	+	155.16
Reactivity		11/13		9/13		11/13		11/13		8/13		10/13	


406

407 \* Time gap between SARS-CoV-2 diagnosis by PCR and collection of blood sample. AU,  
 408 arbitrary units. +, seropositive. -, seronegative. +/-, borderline. Ratios for IgG and IgA ELISA  
 409 indicate the ratio between sample and calibrator. Ratios for the flow cytometric assay indicate  
 410 the ratio between mock MFI and SARS-CoV-2 MFI for a given sample. Red/orange  
 411 background indicates negative/borderline result.




412

413 Figure 1. Representative samples measured in the flow cytometric assay. As described in the  
 414 methods section, 293T cells expressing SARS-CoV-2 S protein and pcDNA3.1-transfected  
 415 cells (mock) were incubated with COVID-19 patient sera (S1-S3) or with negative control  
 416 sera (S4-S6). Bound IgM and IgG were detected with secondary detection antibodies. The left  
 417 plot shows the gating of the target populations considering the co-transfected fluorescent  
 418 proteins as transfection markers (BFP and dsRed). The right histograms depict IgM and IgG  
 419 fluorescence signals in each sample for both cell populations, respectively. The mean  
 420 fluorescence intensity is shown in numbers.




421

422 Figure 2. Analysis of SARS-CoV-2-specific IgM and IgG in serum samples from uninfected  
423 individuals or COVID-19 patients. The flow cytometric serological assay was performed with  
424 samples from the pre-COVID-19 era (n=82), samples from individuals with known endemic  
425 HCoV infection (n=8 before infection, HCoV (end., pre); n=13 after infection, HCoV (end.,  
426 post)), and samples from PCR-positive COVID-19 patients (n=16). Shown are the ratios of  
427 the MFI values for SARS-CoV-2-expressing and mock-transfected cells for IgM (a) and IgG  
428 (b). The cut-off is depicted as dotted line and represents a ratio of 3. Shown are individual  
429 serum samples and the group mean. MFI, mean fluorescence intensity. end, endemic.



430

431 Figure 3. Longitudinal analysis of SARS-CoV-2 seroconversion in two COVID-19 cases. At  
432 each depicted date, serum samples were collected from the respective patient and analysed by  
433 the flow cytometric assay for IgM and IgG. The cut-off is depicted as dotted line and  
434 represents a ratio of the MFI values for SARS-CoV-2-expressing and mock-transfected cells  
435 of 3. Arrows indicate values above the cut-off.



436

437 Figure 4. Quantification of SARS-CoV-2-specific antibody levels by an external ACE-2-Fc  
438 standard. (A) Defined concentrations of the ACE-2-Fc protein were analysed by the flow  
439 cytometric assay in five independent measurements (each symbol representing one  
440 measurement). With the help of this ACE-2-Fc standard, the concentration of a standard  
441 serum was defined. The standard serum was measured in a dilution series by the flow  
442 cytometric assay (B) and the EuroImmun ELISA (C). 4-PL curve fitting (shown with 95%  
443 confidence bands) was used to generate a standard curve for the absolute quantification of  
444 unknown samples. (D) Seven randomly chosen sera from PCR-confirmed COVID-19 patients  
445 were quantified by ELISA and the cytometric assay for SARS-CoV-2-specific IgG. The plot  
446 assesses the correlation between those two assays by spearman's rank correlation coefficient.